In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 2 institutions in 1 country.
Stephanie MedinaDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-1614-5469 Asa A BrockmanDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-0059-0392 Claire E CrossDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-5534-9491 Madeline J HayesDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-3684-9885 Bret C MobleyDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8138-5330 Akshitkumar M MistryVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-7918-5153 Silky ChotaiVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-5981-3231 Kyle D WeaverVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Reid C ThompsonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Lola B ChamblessVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-5864-5387 Rebecca A IhrieDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0003-0439-0141 Jonathan M IrishDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-9428-8866 Vanderbilt University · USVanderbilt University Medical Center · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MSingle-Cell Biology and Data Analysis Shared Resource (SCB-DA SR)U54CA217450 · NCI · VANDERBILT UNIVERSITY · PI WEAVER, ALISSA M · 2018 to 2022
$8.5MSingle Cell Methods for Bioeffector Discovery and AnalysisR01CA226833 · NCI · VANDERBILT UNIVERSITY · PI BRIAN O BACHMANN, Jonathan Michael Irish · 2019 to 2026
$6.1MHallmarks of Protective Immunity in Sequential Rhinovirus Infections in HumansU01AI125056 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2016 to 2020
$4.1MInitiative for Maximizing Student Development (IMSD) at VanderbiltT32GM139800 · NIGMS · VANDERBILT UNIVERSITY · PI RHOADES (STERLING), JULIE A, SEREZANI, C. HENRIQUE · 2021 to 2025
$3.7MIdentifying mTOR Dependent Periods During Brain DevelopmentR01NS118580 · NINDS · VANDERBILT UNIVERSITY · PI ESS, KEVIN C, IHRIE, REBECCA A · 2020 to 2024
$2.1MQuantifying Differences in mTOR Activity and Tumor Development Between Neural Stem Cell MicrodomainsR01NS096238 · NINDS · VANDERBILT UNIVERSITY · PI IHRIE, REBECCA A · 2016 to 2020
$1.7MImmunological Mechanisms of Disease Training ProgramT32AI138932 · NIAID · VANDERBILT UNIVERSITY · PI MAJOR, AMY S, RATHMELL, JEFFREY C. · 2019 to 2023
$1.4MNCI NIH HHS P30 CA068485NCI NIH HHS R01 CA226833NCI NIH HHS U54 CA217450NIAID NIH HHS T32 AI138932NIAID NIH HHS U01 AI125056NIGMS NIH HHS T32 GM139800NINDS NIH HHS R01 NS096238NINDS NIH HHS R01 NS118580
6 · The paper itselfAbstract
Adult IDH-wildtype glioblastoma (GBM) is a highly aggressive brain tumor with no established immunotherapy or targeted therapy. Recently, CD32
Indexed as
CD32cytometryGlioblastomaIL-8M2macrophagesV-SVZ stem cell niche
Identifiers
PMID38585888
PMCPMC10996638
OpenAlexW4393354847
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390